- Home
- MYN vs GOSS Comparison
MYN vs GOSS Comparison
Compare MYN & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYN
- GOSS
- Stock Information
- Founded
- MYN 1992
- GOSS 2015
- Country
- MYN United States
- GOSS United States
- Employees
- MYN N/A
- GOSS N/A
- Industry
- MYN Finance Companies
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- MYN Finance
- GOSS Health Care
- Exchange
- MYN Nasdaq
- GOSS Nasdaq
- Market Cap
- MYN 358.2M
- GOSS 347.8M
- IPO Year
- MYN N/A
- GOSS 2019
- Fundamental
- Price
- MYN $9.31
- GOSS $2.47
- Analyst Decision
- MYN
- GOSS Strong Buy
- Analyst Count
- MYN 0
- GOSS 4
- Target Price
- MYN N/A
- GOSS $8.50
- AVG Volume (30 Days)
- MYN 86.0K
- GOSS 3.1M
- Earning Date
- MYN 01-01-0001
- GOSS 08-05-2025
- Dividend Yield
- MYN 4.12%
- GOSS N/A
- EPS Growth
- MYN N/A
- GOSS N/A
- EPS
- MYN N/A
- GOSS N/A
- Revenue
- MYN N/A
- GOSS $40,237,000.00
- Revenue This Year
- MYN N/A
- GOSS N/A
- Revenue Next Year
- MYN N/A
- GOSS $30.65
- P/E Ratio
- MYN N/A
- GOSS N/A
- Revenue Growth
- MYN N/A
- GOSS N/A
- 52 Week Low
- MYN $8.47
- GOSS $0.66
- 52 Week High
- MYN $10.62
- GOSS $2.65
- Technical
- Relative Strength Index (RSI)
- MYN 48.18
- GOSS 68.08
- Support Level
- MYN $9.20
- GOSS $2.38
- Resistance Level
- MYN $9.33
- GOSS $2.65
- Average True Range (ATR)
- MYN 0.07
- GOSS 0.15
- MACD
- MYN -0.01
- GOSS 0.03
- Stochastic Oscillator
- MYN 50.00
- GOSS 76.67
About MYN Blackrock MuniYield New York Quality Fund Inc.Common Stock
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.